Factors to watch on Nov 11

November 11, 2015 6:12 AM

6 0

The biggest cancer drug maker won U.S. Food and Drug Administration approval for Cotellic to be used in combination with the company's Zelboraf drug to treat BRAF V600 mutation-positive advanced melanoma.

Novartis said its heart failure medicine Entresto(TM) cuts 30-day hospital readmissions.

Also read: McKesson to Pay $150 Million for Failing to Report ‘Suspicious’ Drug Orders

Read more

To category page